GlassScriptPhysician profile
Paul A Fabela
NPI 1700103132
$3,942.66
in general payments reported to CMS, 2019-2025
37 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.40 · 2020: $207 · 2021: $407 · 2022: $537 · 2023: $600 · 2024: $1,017 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,754.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $804.65 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $529.66 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.85 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $232.87 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $221.12 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Glaxosmithkline, LLC. | $192.64 | 2022-2025 | Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $179.95 | 2020-2025 | |
| Abbvie INC. | $145.14 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.12 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $122.13 | 2020-2025 | Trintellix |
| Dexcom, INC. | $112.19 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $104.33 | 2024-2025 | Veozah |
| Cipher Pharmaceuticals US LLC | $84.16 | 2025 | Spinosad, Natroba |
| Merck Sharp & Dohme LLC | $83.00 | 2020-2022 | |
| Corcept Therapeutics | $69.30 | 2025 | Korlym |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $62.69 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $58.40 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.08 | 2022 | |
| Axsome Therapeutics, INC. | $42.07 | 2024-2025 | Sunosi, Auvelity |
| Xeris Pharmaceuticals, INC. | $38.63 | 2025 | Gvoke Hypopen, Keveyis |
| Jazz Pharmaceuticals INC. | $36.28 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $35.41 | 2025 | Rexulti |
| Amarin Pharma, INC. | $34.18 | 2021-2022 | |
| Si-Bone, INC. | $33.83 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.38 | 2022-2024 | |
| Antares Pharma, INC. | $26.47 | 2021-2025 | Xyosted |
| Pfizer INC. | $21.72 | 2025 | |
| Bausch Health US, LLC | $19.00 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.52 | 2022 | |
| Halozyme INC | $18.03 | 2023 | |
| Amgen INC. | $17.84 | 2025 | Otezla, Repatha |
| Seqirus USA INC | $16.74 | 2022 | |
| Ibsa Pharma INC. | $16.28 | 2022 | |
| Hikma Pharmaceuticals USA | $16.03 | 2024 | Ryaltris |
| Optinose US, INC. | $14.99 | 2024 | |
| Sunovion Pharmaceuticals INC. | $14.81 | 2019 | |
| Sumitomo Pharma America, INC. | $14.17 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Fabela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.